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See Article, pages 809–815Persistent hepatitis B virus (HBV) infection has been and still is a
leading cause for end-stage liver disease in endemic regions in
Asia and Africa. In contrast, in the Western hemisphere, the rates
of HBV infection in liver transplant candidates is lower and
declining as reﬂected in a recent UNOS analysis, reporting a
5.3% rate of HBV infection as the cause for liver failure and HBV
associated hepatocellular carcinoma among 48,654 liver trans-
plant candidates in the US [1]. The ongoing worldwide organ
shortage for liver transplantation (LTx) has been a driving force
for exploring new means to expand the pool of potential organ
donors. Depending on the age of acquisition, acute HBV infection
resolves spontaneously in up to 90% of infected adults with an
intact immune system. Consequently, the pool of potential liver
donors includes a fraction of either anti-HBs+/anti-HBc+ or
HBsAg/anti-HBs/anti-HBc+ individuals with normal liver
functions who have such recovered from HBV infection. The size
of this pool is driven by the particular prevalence of HBV infec-
tion in designated regions worldwide ranging between 1.8% and
6% in the US (between 1994 and 2006) as compared for example
to 63% (2003) in Taiwan [2,3]. A retrospective survey among
35,620 cadaveric adult transplant recipients in the US (1994–
2006) identiﬁed up to 8.5% anti-HBc+ donors. Understandably,
the safety of using livers from such potential donors has initially
been challenged due to the presence of occult HBV infection in
some of the grafts, manifested by residual hepatic intra-nuclear
cccHBV-DNA even in anti-HBc+/anti-HBs+ individuals, which
can serve as a template for post transplantation HBV reactivation
in immune suppressed recipients. More than two decades have
passed since the ﬁrst reports on transmission of occult HBV infec-
tion from HBsAg/anti-HBc+ or anti-HBc+/anti-HBs+ liver trans-
plant donors to HBV naïve recipients [4–7]. It soon became clear
that the risk of HBV reactivation or de novo infection in recipients
of such previously infected grafts may reach 75–80% in HBV naïve
recipients, declining to 15–20% in anti-HBc+ or anti-HBs+
patients and to 0–5% in anti-HBs+/anti-HBc+ individuals. Mean-
while the development of potent nucleot(s)ide analogues as wellJournal of Hepatology 20
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Open access under CC BY-NC-ND license.as hepatitis B immune globulin (HBIG) provide excellent means
to protect HBV naïve or even anti-HBc+ liver graft recipients
against either de novo or reactivation of HBV infection.
Consequently there is by now almost worldwide consensus that
anti-HBc+ as well as anti-HBc+/anti-HBs+ grafts can be trans-
planted to matched patients with overt, occult or past HBV infec-
tion (and under certain circumstances in emergency conditions
and with some precautions even to HBV naïve recipients). Recip-
ients of such organs were reported to have an overall similar post
transplant survival (with some exceptions [8]) as compared to
anti-HBc/HBsAg naïve donors [2,9–14]. The current approach
to the utilization of such grafts is reﬂected in the results of a 2007
international survey suggesting that most transplant centres will
accept anti-HBc+ grafts even for HBV naïve recipients [15]. It took
almost a decade to evaluate the advantages, the short term and
intermediate safety and the limitations of using liver transplant
grafts with occult HBV infection for patients with liver failure.
Although data on long-term follow-up and safety in recipients
of anti-HBc+ grafts are still unavailable, there is already a consen-
sus as quoted from a recent editorial in the Journal of Hepatology
by Cholangitas et al.:
‘‘Liver grafts from anti-HBc positive donors can be safely used,
preferentially in HBsAg-positive or anti-HBc/anti-HBs positive
recipients. HBsAg-negative recipients should receive prophylaxis
with lamivudine, while both anti-HBc and anti-HBs positive
recipients may need no prophylaxis at all’’ [14]. A similar view
is expressed in the title of an editorial by M. Prieto ‘‘Antibody
to hepatitis B core antigen-positive grafts: Not perfect but no
longer marginal’’ [12].
Attention is now shifting to explore further means for expan-
sion of the donor pool through utilization of HBsAg+ grafts from
donors with overt HBV infection but with preserved liver func-
tion and without signiﬁcant ﬁbrosis for HBsAg+ recipients.
The ﬁrst case report on the utilization of HBsAg+ grafts
appeared in 1994 [16] followed by more case reports between
2005 and 2007 [16–20]. Single centre reports on small series of
patients receiving HBsAg+ grafts in 6–10 patients [21–23]
followed by a larger study in 92 liver transplant recipients [24],
paved the road for exploring this avenue of salvage further. A
recent retrospective analysis of the US national data base
(N = 78) conﬁrmed that transplantation of HBsAg+ grafts, mainly
in recipients with a history of HBV infection, did not reduce graft
and patients survival post transplantation, provided recipients14 vol. 61 j 717–719
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were protected with anti-viral therapy [25]. In the study using US
national registry data, the 5 year HBsAg+ patient survival was 71%
compared to 71% in the control group with a graft survival of 66%
and 64% for recipients of HBsAg+ grafts and matched controls,
respectively. Yet, the worldwide experience using HBsAg+ liver
grafts is limited. In the present issue of the Journal of Hepatology,
Yu and co-workers report their experience in a cohort of 42 adult
Chinese patients who underwent liver-transplantation with an
HBsAg+ graft [26].
In this study, the investigators have retrospectively compared
the short-term follow-up as well as the clinical, laboratory and
serologic postoperative course and outcome of 42 orthotopic liver
transplant recipients from HBsAg+ donors to 327 LTx recipients
fromHBsAg donors. Among the HBsAg+ positive graft recipients,
38 patients survived more than 1 month and the maximal follow-
up period was about 3 years. The overall mean follow-up for the
recipients of an HBV positive graft was 13.9 ± 11.2 months as
compared to 19 ± 11.8 months for the control group (p 6 0.01).
Among the 327 patients in the control group, 25.7% had appar-
ently some HBVmarker (details not mentioned) as a result of past
exposure to HBVwhile 4/42 LTx patients who received an HBsAg+
graft were apparently HBV naïve.
The main results of the study include: (1) The immediate rates
of postoperative morbidity and mortality as reﬂected by follow-
up of primary graft non-function, acute rejection, biliary compli-
cations and liver function tests were similar in both study groups.
(2) Since HBsAg positivity persists in recipients of HBV infected
grafts, anti-viral treatment with a nucleos(t)ide analogue should
be continued for an indeﬁnite period post operatively but there is
no rational in the administration of HBIG in such patients. (3)
Immune suppressive treatment of HBsAg+ patients receiving an
HBsAg+ graft did not result in overt HBV reactivation. (4) All in
all, transplantation of HBsAg+ grafts from HBV infected patients
with preserved liver functions and presumably no signiﬁcant
liver disease to HBsAg+ recipients is a legitimate means to pro-
vide rescue for LTx candidates when no HBV naïve or anti-
HBc+/HBsAg donors are available.Comments
The results of this study conﬁrm previous retrospective observa-
tions regarding the utility of using HBsAg+ grafts in situations
where no other options such as an HBV naïve cadaveric or living
related donor are available. Thus, these results provide further
justiﬁcation for expanding the donor pool, especially in countries
endemic for HBV such as China where the current prevalence of
HBsAg is around 7% [27], not to speak of a rather high anti-
HBc+ rate. Furthermore, as also reported previously, transplanta-
tion of HBsAg+ grafts may likewise be considered under special
circumstances when other options are unavailable even for HBV
negative recipients (with adequate anti-viral protection) as well
as for anti-HBc+ and or anti-HBs+ patients with liver failure.
The paper by Yu and coworkers is well written although the
study design and results have some limitations as acknowledged
by the authors. These include among others the retrospective and
partially controlled design of the study; the relatively short-term
follow-up, which does not enable a ﬁrm conclusion regarding the
long-term safety and assessment of HBV associated complica-
tions. Interestingly, most organ recipients from HBeAg+ donors
maintained an HBeAg+ status post transplantation, regardless of718 Journal of Hepatology 201their original HBeAg or anti-HBe status prior to transplantation.
This observation justiﬁes a more in depth analysis including
quantitative serum, intrahepatic and cccHBV-DNA measure-
ments, genotyping and comparative sequencing of HBV-DNA
with phylogenetic analysis in donors and recipients alike. In this
context it is worthwhile to cite a previous report from Hong-Kong
[28] and an accompanying editorial [29] describing a so called
competition between two occult hepatitis B virus infections,
which originated from an anti-HBc+ donor whose liver was trans-
planted to a patient with occult HBV who has previously been
infected with HBV as well and treated with lamivudine. There-
fore, further studies should include long-term monitoring of
these parameters, which should lead to better understanding of
the molecular pathophysiology in such patients, including the
impact of genotype on the natural history of the graft. Finally,
there are other, albeit experimental means for providing protec-
tion against HBV to graft recipients which remain to be explored,
including adoptive transfer of immunity from anti-HBs positive
donors to recipients [30] or immunization with a PreS/S vaccine
[31,32].
In conclusion, the results of this chinese study by Yu and
co-workers conﬁrm and complement a number of previous obser-
vations from Europe and the US regarding the utility and short-
term safety of LTx using HBsAg+ donors for HBsAg+ recipients.
At present, data from a prospectively adequately controlled trial
are unavailable. The logistics of conducting such a study in the
future are complex and it is doubtful that results will be available
in the near future. Meanwhile, and until then, it is the opinion of
this viewer that the already obtained evidence justiﬁes the use
of HBsAg+ donors for patient persistently infected with HBV and
liver failure when no other donor is available. However, in the
absence of data regarding the safety of using grafts from HBsAg(+)
donors with delta virus co-infection, or vise versa transplanting
HBsAg(+) grafts to delta virus infected recipients, caution is
advised regarding approval of transplantation in such a situation.
Not less important, further long-term follow-up is required for
those HBsAg+ LTx recipients who have already received a graft
from an HBsAg+ donor.Conﬂict of interest
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